^
Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Epkinly (epcoritamab-bysp) (CD20 inhibitor, CD3 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
016 | SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI-TUMOR ACTIVITY
Published date:
06/09/2021
Excerpt:
Adults with R/R CD20+ B-NHL received flat-dose 1 mL SC epcoritamab (step-up dosing approach) in 28-day cycles…ORR for patients with FL at doses ≥12 mg (n = 5) was 80% (CR = 60%; PR = 20%); ORR for patients with MCL at doses ≥0.76 mg (n = 4) was 50% (CR = 25%; PR = 25%).
